Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

AIM ImmunoTech Inc

Healthcare US AIM

0.37215USD
-0.0108(2.81%)

Last update at 2026-06-23T14:54:00Z

Day Range

0.360.37
LowHigh

52 Week Range

0.4714.92
LowHigh

Fundamentals

  • Previous Close 0.38
  • Market Cap3.98M
  • Volume354820
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-11.45400M
  • Revenue TTM0.09M
  • Revenue Per Share TTM0.05
  • Gross Profit TTM -0.04000M
  • Diluted EPS TTM-8.62

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2023-01-31 2022-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2023-01-31 2022-12-31
Income before tax -13.95800M -17.32000M -28.96200M -19.44500M -19.44500M
Minority interest - - - - -
Net income -13.95800M -17.32000M -28.96200M -21.08600M -21.08600M
Selling general administrative 7.70M 13.71M 21.14M 13.07M 13.07M
Selling and marketing expenses - - 0.62M - -
Gross profit -0.25000M 0.14M 0.16M -19.78200M -19.78200M
Reconciled depreciation 0.21M 0.25M - 0.26M 0.26M
Ebit -10.52600M -16.73500M -31.91600M -19.92300M -19.44500M
Ebitda -10.31600M -16.48900M -31.67800M -17.54800M -19.86900M
Depreciation and amortization 0.21M 0.25M 0.24M 2.38M -0.42400M
Non operating income net other - - - - -
Operating income -10.52600M -19.77200M -31.91600M -19.92300M -19.92300M
Other operating expenses 10.61M 19.94M 32.12M 20.06M 20.06M
Interest expense 0.81M 0.58M - 0.48M 0.48M
Tax provision - - - - -
Interest income 3.18M 5.19M - 1.05M 0.63M
Net interest income 2.37M 4.61M - 0.63M 0.63M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - 1.64M 1.64M
Total revenue 0.09M 0.17M 0.20M 0.14M 0.14M
Total operating expenses 10.28M 19.91M 32.08M 20.06M 20.06M
Cost of revenue 0.34M 0.03M 0.04M 19.92M 19.92M
Total other income expense net -3.43200M 2.45M 2.95M 0.48M 0.48M
Discontinued operations - - - - -
Net income from continuing ops -13.95800M -17.32000M - -19.44500M -19.44500M
Net income applicable to common shares - -17.32000M - -19.44500M -
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2023-01-31 2022-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2023-01-31 2022-12-31
Total assets 5.78M 8.61M 19.38M 40.49M 40.49M
Intangible assets 1.66M 2.59M 2.31M 1.94M 1.94M
Earning assets - - - - -
Other current assets 2.29M 0.20M 0.60M 0.46M 0.46M
Total liab 15.56M 9.93M 9.15M 2.02M 2.02M
Total stockholder equity -9.78300M -1.32200M 10.23M 38.47M 38.47M
Deferred long term liab - - - - -
Other current liab 0.80M 0.61M 1.76M 0.81M 0.81M
Common stock 0.00300M 0.07M 0.05M 0.05M 0.05M
Capital stock 0.00300M 0.07M - 0.74M 0.74M
Retained earnings -440.78600M -426.82800M -409.50800M -380.54600M -380.54600M
Other liab - - - - -
Good will - - - - -
Other assets - -4.43200M 0.00000M 1.20M -
Cash 0.93M 1.70M 5.44M 27.05M 27.05M
Cash and equivalents - 1.70M - 27.05M -
Total current liabilities 6.22M 9.54M 8.65M 1.36M 1.36M
Current deferred revenue - - -0.22300M - -
Net debt 3.96M 1.24M -4.72100M -26.21600M -26.21600M
Short term debt 3.80M 2.55M 0.45M 0.18M 0.18M
Short long term debt 3.55M 2.31M - - -
Short long term debt total 4.90M 2.94M 0.72M 0.84M 0.84M
Other stockholder equity 431.00M 425.44M 419.00M 418.27M 418.27M
Property plant equipment - 0.73M - 1.02M -
Total current assets 3.29M 4.18M 14.56M 36.32M 36.32M
Long term investments - - - - -
Net tangible assets - - - - -
Short term investments 0.06M 2.28M 7.63M 7.14M 7.14M
Net receivables 0.00700M - 1.18M 1.68M 1.68M
Long term debt 0.93M - - - -
Inventory - - -0.30200M - -
Accounts payable 1.63M 6.38M 6.44M 0.38M 0.38M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - 0.00000M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.83M 1.11M 1.69M 1.20M 1.20M
Deferred long term asset charges - - - - -
Non current assets total 2.49M 4.43M 4.83M 4.17M 4.17M
Capital lease obligations 0.42M 0.63M - 0.84M 0.84M
Long term debt total - 0.00000M - 0.00000M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2023-01-31 2022-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2023-01-31 2022-12-31
Investments 2.23M 4.71M - 10.99M 10.99M
Change to liabilities - - - - -
Total cashflows from investing activities 1.85M 4.71M - 10.99M -
Net borrowings 2.09M 2.25M - - -
Total cash from financing activities 10.39M 6.44M 0.48M 0.08M 0.08M
Change to operating activities - - - - -
Net income -13.95800M -17.32000M -28.96200M -19.44500M -19.44500M
Change in cash 1.28M -3.73800M -21.61400M -5.04000M -5.04000M
Begin period cash flow 1.70M 5.44M 27.05M 32.09M 32.09M
End period cash flow 2.98M 1.70M 5.44M 27.05M 27.05M
Total cash from operating activities -10.95700M -14.88800M -21.26700M -16.10800M -16.10800M
Issuance of capital stock 8.30M 0.89M - 0.08M 0.08M
Depreciation 0.04M 0.25M 0.24M 0.26M 0.26M
Other cashflows from investing activities 0.02M -0.63100M - 11.26M -
Dividends paid - - - - -
Change to inventory - - - - 0.04M
Change to account receivables -0.00700M 1.18M 0.49M 0.00000M -0.03500M
Sale purchase of stock - 4.20M - 0.08M -
Other cashflows from financing activities 10.39M 3.30M 0.48M 10.99M 10.99M
Change to netincome - - - - -
Capital expenditures 0.38M 0.02M 0.58M 0.27M 0.27M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.87800M 0.30M 1.06M 0.97M 0.97M
Stock based compensation 0.06M 0.69M 0.24M 0.95M 0.95M
Other non cash items 3.78M 1.20M 0.31M 0.96M 0.96M
Free cash flow -10.95700M -14.90600M -21.85200M -16.37900M -16.37900M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AIM
AIM ImmunoTech Inc		 -0.0108 2.81% 0.37 - 2.01 45.18 2.73 66.36 0.49
NVO
Novo Nordisk A/S		 1.15 2.51% 47.03 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.41 0.30% 468.20 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.50 1.06% 619.00 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. The company is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

AIM ImmunoTech Inc

2117 SW Highway 484, Ocala, FL, United States, 34473

Key Executives

Name Title Year Born
Mr. Thomas K. Equels Esq., J.D., M.S. Exec. Vice Chairman, CEO & Pres 1953
Mr. Peter W. Rodino III, Esq., J.D. COO, Exec. Director of Gov.al Relations, Gen. Counsel & Sec. 1951
Mr. Robert Dickey IV, M.B.A. Chief Financial Officer 1956
Dr. David R. Strayer M.D. Chief Scientific Officer & Medical Director 1946
Ann Marie E. Coverly Director of Admin. & HR and Deputy Investor Relations Coordinator NA
Dr. Carol A. Smith Chief Manufacturing Officer & Deputy Chief Scientific Officer 1951
Jodie Pelz Controller NA
Dr. Ralph Christopher Cavalli Ph.D. VP of QC & Manufacturing 1958
Mr. Thomas K. Equels Esq., J.D., M.S. Executive Vice Chairman, CEO & President 1953
Mr. Robert Dickey IV, M.B.A. Chief Financial Officer 1955

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.